Tag: Btk inhibitors

BTK inhibitors have revolutionized the treatment landscape for many B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), by providing a highly effective alternative to traditional chemotherapy. The core principle behind these targeted therapies is understanding **what is the mechanism of action of BTK inhibitors** and how they disrupt the specific pathways that fuel cancer growth.

The term "Bt drug" is not a single entity but can refer to several distinct substances or concepts within medicine, including Botulinum Toxin, Bruton's Tyrosine Kinase (BTK) inhibitors, and a potentially dangerous prescription abbreviation. A lack of clarification can lead to significant misunderstanding and potential medication errors, making it critical to understand the correct context when this term is used.